

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zhongzhi Pharmaceutical Holdings Limited**

**中智藥業控股有限公司**

*(Incorporated in Cayman Islands with limited liability)*

**(Stock Code: 3737)**

### **POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 12 OCTOBER 2018**

The Board is pleased to announce that the resolution proposed at the EGM held on 12 October 2018 was duly passed by the Shareholders by way of poll at the EGM.

The board of directors (the “**Board**”) of Zhongzhi Pharmaceutical Holdings Limited (the “**Company**”) is pleased to announce that the proposed resolutions as set out in the notice of extraordinary general meeting of the Company dated 20 September 2018 were duly passed by the shareholders of the Company (the “**Shareholders**”) by way of poll at the extraordinary general meeting of the Company held on 12 October 2018 (the “**EGM**”).

As at the date of the EGM, the total number of shares in the issued share capital of the Company was 840,000,000 shares. There were no shares entitling the Shareholders to attend and abstain from voting in favour of any of the resolutions proposed at the EGM. None of the Shareholders were required to abstain from voting at the EGM. Accordingly, there were a total of 840,000,000 shares, representing the entire issued share capital of the Company, entitling the Shareholders to attend and vote for or against the resolutions proposed at the EGM.

The Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of votetaking.

The poll results in respect of all the resolutions at the EGM are set out as follows:

ORDINARY RESOLUTIONS		Number of votes (%)	
		FOR	AGAINST
1.	(a) the declaration and payment of an interim dividend of HK2.65 cents per ordinary share out of the share premium account of the Company (the “ <b>Interim Dividend</b> ”) to shareholders of the Company whose names appear on the register of members of the Company on the record date fixed by the board of Directors for determining the entitlements to the Interim Dividend be and is hereby approved; and	577,054,000 (100%)	0 (0.00%)
	(b) any Director of the Company be and is hereby authorised to take such action, do such things and execute such further documents as the director may at his absolute discretion consider necessary or desirable for the purpose of or in connection with the implementation of the payment of the Interim Dividend.	577,054,000 (100%)	0 (0.00%)
2.	(a) the declaration and payment of a special dividend of HK\$1.70 cents per ordinary share out of the share premium account of the Company (the “ <b>Special Dividend</b> ”) to shareholders of the Company whose names appear on the register of members of the Company on the record date fixed by the board of Directors for determining the entitlements to the Special Dividend be and is hereby approved; and	577,054,000 (100%)	0 (0.00%)
	(b) any Director of the Company be and is hereby authorised to take such action, do such things and execute such further documents as the director may at his absolute discretion consider necessary or desirable for the purpose of or in connection with the implementation of the payment of the Special Dividend.	577,054,000 (100%)	0 (0.00%)

As more than 50% of the votes were cast in favour of each of the above resolutions no.1 to no.2, all such resolutions were duly passed as ordinary resolutions of the Company.

By order of the Board  
**Zhongzhi Pharmaceutical Holdings Limited**  
**Mr. Lai Zhi Tian**  
*Chairman and Executive Director*

Hong Kong, 12 October 2018

*As at the date of this announcement, the Board comprises nine Directors. The executive Directors are Mr. Lai Zhi Tian, Mr. Lai Ying Feng, Mr. Cao Xiao Jun and Mr. Cheng Jin Le. The non-executive Directors are Ms. Jiang Li Xia and Mr. Yang Ai Xing. The independent non-executive Directors are Mr. Ng Kwun Wan, Mr. Wong Kam Wah and Mr. Zhou Dai Han.*